Dr.ย Saadย Usmani
MD, MBA, FACP, FASCO
Chief, Myeloma Service
corporate_fareMemorial Sloan Kettering Cancer Center, New York
Saad Usmani
MD, MBA, FACP, FASCO
Dr. Saad Z. Usmani is a leading hematologist-oncologist and myeloma specialist at Memorial Sloan Kettering Cancer Center in New York, where he serves as Chief of the Myeloma Service. He has more than 14 years of focused experience treating patients with multiple myeloma, smoldering myeloma, MGUS, light chain amyloidosis, and related plasma-cell disorders.
Dr. Usmani received his medical education at Allama Iqbal Medical College in Lahore, Pakistan, and completed residency training at Sinai-Grace Hospital/Wayne State University in Detroit before undertaking a fellowship in hematology and medical oncology at the University of Connecticut Health Center. He built his academic career first at the Myeloma Institute for Research & Therapy at the University of Arkansas for Medical Sciences, then as inaugural Division Chief of Plasma Cell Disorders and Director of Clinical Research for Hematologic Malignancies at Levine Cancer Institute/Atrium Health, before joining MSK in 2021. He has authored or co-authored more than 370 peer-reviewed manuscripts, contributed to development of anti-CD38 monoclonal antibodies, bispecific antibodies, and CAR T-cell therapies, and holds faculty appointment as Professor of Clinical Medicine at Weill Cornell Medical College. His treatment philosophy centres on patient education, individualised planning, and supporting patients and families throughout the disease journey.
CancerFax can coordinate medical-record review, second-opinion submissions, and consultation support for international patients seeking care from Dr. Usmani at MSK.
Why Consider Dr. Saad Usmani?
Dr. Usmani leads one of the most specialised myeloma programmes in the world at Memorial Sloan Kettering Cancer Center, combining deep clinical expertise with active involvement in cutting-edge therapy development for multiple myeloma.
Areas of Specialisation
Focused expertise in multiple myeloma, plasma-cell disorders, and advanced cellular therapies
Dr. Usmani's clinical practice is centred entirely on multiple myeloma and related plasma-cell disorders, spanning newly diagnosed disease, high-risk presentations, early precursor conditions, and relapsed or refractory cases.
Multiple Myeloma & Plasma-Cell Disorders
Comprehensive management across the full spectrum of myeloma and plasma-cell disease.
- arrow_rightNewly diagnosed multiple myeloma, including transplant-eligible patients
- arrow_rightHigh-risk and hard-to-treat myeloma
- arrow_rightRelapsed and refractory multiple myeloma
- arrow_rightExtramedullary myeloma
- arrow_rightMonoclonal gammopathy of undetermined significance (MGUS)
- arrow_rightSmoldering multiple myeloma and progression risk monitoring
- arrow_rightLight chain amyloidosis
Cellular & Immunotherapy
Advanced treatment modalities for eligible myeloma patients, including novel cellular and immune-based approaches.
- arrow_rightCiltacabtagene autoleucel and other CAR T platforms for relapsed myeloma
- arrow_rightPatient selection and eligibility assessment for cellular therapy
- arrow_rightTeclistamab and anti-BCMAxCD3 bispecific strategies for relapsed or refractory disease
- arrow_rightTrial-based access to next-generation bispecific agents
- arrow_rightAnti-CD38 monoclonal antibody regimens including daratumumab-based combinations
- arrow_rightCheckpoint inhibitor strategies where applicable in plasma-cell disease
Bone Marrow Transplant
Transplant-based approaches for eligible patients as part of a comprehensive myeloma treatment strategy.
- arrow_rightTransplant eligibility assessment and planning
- arrow_rightIntegration of transplant into upfront and salvage myeloma treatment plans
Procedures & Treatments
Clinical services and treatment approaches at Memorial Sloan Kettering Cancer Center
Dr. Usmani provides specialised medical oncology services for patients with multiple myeloma and plasma-cell disorders, with access to MSK's clinical trial portfolio and advanced cellular therapy programmes.
Systemic Myeloma Treatment
Medical OncologyEvidence-based drug treatment planning for multiple myeloma across all lines of therapy.
Cellular Therapy
TransplantAdvanced cellular therapy options for eligible patients, including CAR T-cell therapy and autologous transplant.
Targeted & Novel Therapy
Targeted TherapyPrecision approaches guided by disease biology, including bispecific antibodies and molecularly directed treatment.
Disease Monitoring & Response Assessment
MonitoringOngoing disease surveillance, response tracking, and management of early plasma-cell conditions.
Second Opinion & Complex Case Review
Second OpinionExpert second-opinion consultations for patients with newly diagnosed, relapsed, or high-risk myeloma.
Research & Publications
Clinical and translational research in multiple myeloma and plasma-cell disorders
Dr. Usmani is one of the most prolific researchers in multiple myeloma globally, with more than 370 peer-reviewed manuscripts and leadership roles in major myeloma clinical trials and cooperative group committees.
Dr. Usmani is associated with active clinical trials at MSK in multiple myeloma. CancerFax can assist with trial eligibility enquiries and case submission to the MSK team.
Education & Training
Dr. Usmani completed his medical education in Pakistan before undertaking postgraduate training in the United States, with subspecialty fellowship training in hematology and medical oncology.
Clinical Experience
Dr. Usmani has held senior academic and clinical leadership positions in myeloma across three major US cancer institutions, culminating in his appointment as Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center in 2021.
Languages & International
Dr. Usmani consults in the following languages.
CancerFax can coordinate professional medical interpreter support for international patients seeking consultation with Dr. Usmani.
CancerFax can coordinate professional medical interpreter support for international patients when required.
How CancerFax Helps You Access Dr. Saad Usmani
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Saad Usmani's team โ with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history โ prepared as a structured clinical summary for Dr. Saad Usmani's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Saad Usmani before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Saad Usmani's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Saad Usmani's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Saad Usmani's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Dr. Saad Usmani
Dr. Saad Usmani specialises in hematology-oncology with a primary focus on multiple myeloma and related plasma-cell disorders, including smoldering myeloma, MGUS, and light chain amyloidosis. He is also a recognised expert in CAR T-cell therapy, bispecific antibody therapy, and bone marrow transplant for myeloma.
Dr. Usmani is based at Memorial Sloan Kettering Cancer Center in New York, United States, where he serves as Chief of the Myeloma Service. He also holds a faculty appointment as Professor of Clinical Medicine at Weill Cornell Medical College.
CancerFax can coordinate medical-record review, second-opinion submissions, and consultation support for international patients seeking care from Dr. Usmani at Memorial Sloan Kettering Cancer Center, subject to MSK availability and case acceptance.
Submit your medical records and pathology reports through CancerFax. The CancerFax team will review the documents, prepare the case, and coordinate the next steps with the MSK team on your behalf, subject to availability and case acceptance.
A second-opinion request can be submitted through CancerFax with the patient's pathology reports, imaging, bone marrow biopsy results, treatment history, and relevant laboratory findings. The final consultation format and availability are subject to Dr. Usmani's schedule at MSK.
Yes. Dr. Usmani is associated with active clinical trials at Memorial Sloan Kettering Cancer Center in multiple myeloma, including studies involving CAR T-cell therapy and bispecific antibody approaches for relapsed, refractory, and newly diagnosed myeloma. CancerFax can assist with trial eligibility enquiries.
Dr. Usmani consults in English, Hindi, Urdu, and Punjabi, as listed on his Memorial Sloan Kettering Cancer Center profile.
Memorial Sloan Kettering Cancer Center states that Dr. Usmani has more than 14 years of experience caring for patients with multiple myeloma and plasma-cell disorders.
Connect with Saad Usmani Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.